anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A patient care management system for assisting a physician in monitoring drug use by a patient. The system receives drug dispensation data for a drug, on the basis of which the system determines drug supply availability data. The drug supply availability data is indicative of periods of time during which the drug was available in non-duplicate supply, or in oversupply, or in insufficient supply. The periods of time are displayed with respect to a common time base. Each degree of supply availability is visually displayed via a graphical user interface using, e.g., a color coded scheme, so as to be distinguishable by a user. This allows a physician to rapidly assess over-consumption or compliance problems. Plural drugs may be monitored on a single display screen. The system may also be adapted to allow an prescribing physician to assess refill compliance, hospitalization periods and prescription drug costs.
Xyrem is a central nervous system (CNS) depressant. In adult clinical trials at recommended doses, obtundation and clinically significant respiratory depression occurred in patients treated with Xyrem. Xyrem is contraindicated in combination with alcohol and sedative hypnotics. The concurrent use of Xyrem with other CNS depressants, including but not limited to opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, sedating anti-epileptic drugs, general anesthetics, muscle relaxants, and/or illicit CNS depressants, may increase the risk of respiratory depression, hypotension, profound sedation, syncope, and death. If use of these CNS depressants in combination with Xyrem is required, dose reduction or discontinuation of one or more CNS depressants (including Xyrem) should be considered. In addition, if short-term use of an opioid (e.g., post- or perioperative) is required, interruption of treatment with Xyrem should be considered.

Healthcare providers should caution patients about operating hazardous machinery, including automobiles or airplanes, until they are reasonably certain that Xyrem does not affect them adversely (e.g., impair judgment, thinking, or motor skills). Patients should not engage in hazardous occupations or activities requiring complete mental alertness or motor coordination, such as operating machinery or a motor vehicle or flying an airplane, for at least 6 hours after taking Xyrem. Patients should be queried about CNS depression‐related events upon initiation of Xyrem therapy and periodically thereafter.

Xyrem is available only through a restricted program under a REMS [see Warnings and Precautions (5.3)].
Participants with BBS received setmelanotide at a dose of 0.5 mg QD via SC injection for 52 weeks. The dose was escalated by increments of 0.5 mg every 2 weeks, if tolerated, at the dose escalation visits (Weeks 2, 4, and 6) to a maximum dose of 0.5 to 2.0 mg QD with the maximum dose based on body weight. Following the last dose in this study, participants who were considered likely to benefit from continued setmelanotide treatment and who had completed this trial could be eligible to enter an open-label long-term extension (LTE) trial with setmelanotide.
On the match day, 500 ml received received orally immediately post-match and then at +3h and +6h. On the remaining days, 500 ml daily with breakfast.
The use of grimace scales enables the clinical identification of changes in the facial expressions of animals caused by pain. The Horse Grimace Scale (HGS) is one such tool, comprising a pain coding system based on facial expressions and assessing six Facial Action Units (FAUs). Each FAU is accompanied by descriptions and anatomical details to assist the evaluator. However, the morphological descriptions for certain FAUs in the HGS are not sufficiently detailed, potentially hindering accurate interpretation. This study is an analytical investigation aimed at enhancing the morphoanatomical details in the HGS and providing raters with more comprehensive materials for pain evaluation in horses using this scale. To achieve this, detailed anatomical analyses were conducted using established references in veterinary anatomy. Initially, we propose substituting the term 'ear' with 'auricle' or 'pinna' and replacing 'area above the eye' with 'supraorbital region' for anatomical accuracy. Additionally, we introduce detailed morphoanatomical descriptions that identify specific landmarks, with the goal of ensuring more consistent application of the HGS and reducing interpretation variability. Furthermore, this study provides an explanation of the muscles involved in the investigated FAUs. These adjustments on the descriptions and evaluations remain unverified, however it is anticipated that the descriptive enhancements lead us to understand that higher interobserver reliability can be achieved for each of the FAUs.
A disease classification code prediction method is implemented with an operation device. The operation device is loaded with a code prediction model for predicting a disease classification code to which a patient corresponds. The disease classification code prediction method includes the following steps: (A) the operation device receiving basic data related to a patient-to-be-analyzed and diagnosis data related to the examination of the patient-to-be-analyzed in a hospital and then applying a natural language processing algorithm to acquire a characteristic vector according to the basic data and the diagnosis data; and (B) the operation device applying the code prediction model to acquire a disease classification code corresponding to the patient-to-be-analyzed according to the characteristic vector. The operation device is further loaded with multiple training data corresponding to multiple different patients. Each training data includes training basic data related to a corresponding patient, a training diagnosis data related to the examination of the corresponding patient in the hospital, and a disease classification code corresponding to the patient. Before step (A), the following steps are implemented: (C) for the training basic data and the training diagnosis data of each training data, the operation device applies the natural language processing algorithm to acquire a training characteristic vector according to the training basic data and the training diagnosis data; and (D) the operation device applying a machine learning algorithm to acquire the code prediction model according to the training characteristic vector and the disease classification code corresponding to the training data.
Alzheimer's disease (AD), a neurodegenerative condition previously known to affect the older population, is also now seen in younger individuals. AD is often associated with cognitive decline and neuroinflammation elevation primarily due to amyloid β (Aβ) accumulation. Multiple pathological complications in AD call for therapies with a wide range of neuroprotection. Our study aims to evaluate the effect of N-acetyl-L-tryptophan (NAT) in ameliorating the cognitive decline and neuroinflammation induced by Aβ 1-42 oligomers and to determine the therapeutic concentration of NAT in the brain. We administered Aβ 1-42 oligomers in rats via intracerebroventricular (i.c.v.) injection to induce AD-like conditions. The NAT-treated animals lowered the cognitive decline in the Morris water maze characterized by shorter escape latency and increased path efficiency and platform entries. Interestingly, the hippocampus and frontal cortex showed downregulation of tumor necrosis factor, interleukin-6, and substance P levels. NAT treatment also reduced acetylcholinesterase activity and total and phosphorylated nuclear factor kappa B and Tau levels. Lastly, we observed upregulation of cAMP response element-binding protein 1 (CREB1) signaling. Surprisingly, our HPLC method was not sensitive enough to detect the therapeutic levels of NAT in the brain, possibly due to NAT concentrations being below the lowest limit of quantification of our validated method. To summarize, the administration of NAT significantly lowered cognitive decline, neuroinflammatory pathways, and Tau protein and triggered the upregulation of CREB1 signaling, suggesting its neuroprotective role in AD-like conditions.
The invention relates to an application of chiral manganese nano particles in preparing a medicament for treating bone defects, and belongs to the technical field of material chemistry. The chiral manganese nanoparticle is synthesized by taking amino acid as chiral ligand. The invention comprises the effect of chiral manganese nanoparticle treatment on mouse osteoblasts and osteoclasts and the therapeutic effect of the chiral manganese nanoparticle treatment on bone defect mice. By orally administering the chiral manganese nano particles, the defects of potential disease transmission risk, immune rejection and the like caused by bone grafting can be avoided. The administration is simple, painless and more cost-effective. The chiral manganese nanoparticle has good biological safety, and can be used for treating bone diseases such as bone injury and the like.
Daphne genkwa (D. genkwa) is the dried flower buds of a Chinese medicinal plant with multiple biological activities. Response surface methodology (RSM) combined with artificial neural network (ANN) techniques were utilized to optimize ultrasound-assisted extraction conditions for D. genkwa. Antioxidant activity and anti-inflammatory and analgesic properties of total flavonoids from D. genkwa (TFDG) were assessed. Optimal conditions involving ultrasonic power of 225 W, 30 min extraction time, 30 mL/g liquid-solid ratio, 60 °C extraction temperature, and 70% ethanol concentration yielded a maximum total flavonoids content (TFC) of 5.41 mg/g. After microporous resin purification, four specific flavonoids in D. genkwa were identified and quantified using high-performance liquid chromatography (HPLC). The TFDG demonstrated potent antioxidant activity, with a 94% rate of scavenging the 2, 2-diphenyl-1-picrylhydrazyl (DPPH). Furthermore, TFDG exhibited pain-alleviating properties in hot plate and acetic acid-induced writhing tests and noteworthy inhibitory effects on xylene-induced ear swelling in mice. The total flavonoids extracted by ultrasound had excellent biological activity. This establishes a foundation for further investigation into the potential medical value of D. genkwa.
Participants receive vorolanib PO QD on days 1-56 and nivolumab IV over 30 minutes every two weeks (i.e. on Days 1, 15, 29, and 43 of each 56-day cycle) for the first two treatment cycles. After which, the treatment schedule can change to every four weeks (i.e., on Days 1 and 29 of each 56-day cycle) if the patient is not exhibiting disease progression.
PTSD is the most common mental health diagnosis affecting service men and women who have served in Iraq and Afghanistan (OEF/OIF). Despite unprecedented efforts by the Dept. of Defense (DoD) and Dept. of Veterans Affairs (VA) to treat these service personnel with mental disorders, significant gaps in the continuum of care for psychological health remain, specifically related to which services are offered, where services are offered, and who receives services. The DoD and VA have also attempted to address problems with accessibility through the development of a video teleconference (VTC) network to ensure that service members have access to top-quality specialized medical care regardless of their geographical location. Provision of medical treatment over VTC is often referred to as telemedicine; telemental health (TMH) refers to the provision of mental health treatment over the same system. A handful of studies have shown that psychiatry (primarily medication management) delivered over TMH systems can be as effective as face-to-face (FTF) treatment as long as the equipment and band-width are capable of delivering the communication in near real time.TMH is an increasingly common method of providing psychological treatment to service members with PTSD and other mental health problems, and yet there are no randomized trials of TMH provision of an empirically validated treatment for PTSD compared with FTF treatment. Therefore, this study aims to evaluate the treatment outcomes of patients with PTSD treated with CPT either remotely via TMH or traditionally in FTF treatment.
Cachexia is a muscle-wasting syndrome commonly observed in patients with cancer, which can significantly worsen clinical outcomes. Because of a global rise in obesity, the coexistence of cachexia in obese individuals poses unique challenges, with the impact of excessive adiposity on cachexia severity and underlying pathophysiology not well defined. Understanding the interplay between cachexia and obesity is crucial for improving diagnosis and treatment strategies for these patients; therefore, the present study examined differences in cachexia between lean and obese mice bearing Lewis lung carcinoma (LLC) tumors. Nine-week-old, male C57Bl6J mice were placed on either a chow or a high-fat diet (HFD) for 9 wk. After the diet intervention, mice were inoculated with LLC or vehicle. Markers of cachexia, such as body and muscle loss, were noted in both chow and HFD groups with tumors. Tumor weight of HFD animals was greater than that of chow. LLC tumors reduced gastrocnemius, plantaris, and soleus mass, regardless of diet. The tibialis anterior and plantaris mass and cross-sectional area of type IIb/x fibers in the gastrocnemius were not different between HFD-chow, HFD-tumor, and chow-tumor. Using RNA sequencing (RNA-seq) of the plantaris muscle from chow-tumor and HFD-tumor groups, we identified ∼400 differentially expressed genes. Bioinformatic analysis identified changes in lipid metabolism, mitochondria, bioenergetics, and proteasome degradation. Atrophy was not greater despite larger tumor burden in animals fed an HFD, and RNA-seq data suggests that partial protection is mediated through differences in mitochondrial function and protein degradation, which may serve as future mechanistic targets.NEW & NOTEWORTHY This study provides timely information on the interaction between obesity and cancer cachexia. Lean and obese animals show signs of cachexia with reduced body weight, adipose tissue, and gastrocnemius muscle mass. There was not significant wasting in the tibialis anterior, plantaris, or fast twitch fibers in the gastrocnemius muscle of obese animals with tumors. RNA-seq analysis reveals that obese tumor bearing animals had differential expression of mitochondria- and degradation-related genes, which may direct future studies in mechanistic research.
The invention relates to isopentenyl naphthoquinone obtained in the active fraction for promoting blood circulation to remove blood stasis in clinopodium chinense (Benth.) O. Kuntze. in a novel structure. A preparation method comprises the steps of extracting the dried overground part of clinopodium chinense (Benth.) O. Kuntze. by water; purifying and enriching an extract by macroporous resin to obtain a 50-95% ethanol eluate; then, enriching through alkali dissolution and acid deposition, and refining to obtain the active fraction of clinopodium chinense (Benth.) O. Kuntze.. One novel isopentenyl naphthoquinone is separated from the active fraction of clinopodium chinense (Benth.) O. Kuntze. through various separating technologies such as column chromatography and the like. The separated compound is identified by applying modern spectrum technologies (IR, UV, MS, 1D, 2D-NMR), and the compound is named as 2, 2-dimethyl-3, 10-dihydroxy-3, 4, 4a, 10b-tetrahydro-5H-naphtho[1, 2-b]-pyran-6-one (1). The novel isopentenyl naphthoquinone is characterized in that the compound is a polymer of naphthoquinone and/or isoamylene in a novel structure.
FIELD: medicine, therapy. SUBSTANCE: method involves administration to patient the injection of drug - aloe liquid extract for injection or its combination with different special additions: nicotinic acid and/or anesthetics. Injection is carried out by pair and symmetrical route into submucosa posterior oral pharynx wall, at least twice at interval for 2-3 days. Maximal treatment duration is 6-7 days. Agent can be used in broad group of patients. EFFECT: high therapeutic effect, high aversive effect, decreased time of treatment. 4 cl, 4 ex
Participants will continue with their usual care, consistent with standard National Health Service (NHS) care in this population. Usual physiotherapy care is provided, up to 2 times per day, 4 to 5 days per week, each lasting up to 90 minutes. Physiotherapists provide a combination of group exercise and one to one function-orientated physiotherapy sessions to improve balance, general muscle strength, wheelchair and/or transfer skills.
In the Placebo-MT+TENS group, the experimental set-up and protocol will be the same as in the MT+TENS group, except that the reflecting surface of the angle-adjustable mirror was covered with paper. After 15 minutes of priming, all subjects will perform 60 minutes of lower limb task-oriented training.
FIELD: medicine, ophthalmology, homeopathy. SUBSTANCE: invention proposes agent containing Calcarea fluorica, Arnica, Conium in the definite dilutions and sugar as a neutral carrier. Claimed preparation ensures to decrease time of opacity resolution, recover vision in large percent of cases. Also, agent has no contraindications, it does not show allergic responses and can be used both in monotherapy and in combination with other drugs. EFFECT: enhanced effectiveness of agent. 2 cl, 2 ex
Metallopanstimulin-1 (MPS-1) is a multifunctional ribosomal protein. MPS-1 is a 10 kD zinc finger protein (ZFP) that is present in all tissues and expressed in increased quantities in a wide variety of proliferating tissues and malignancies. The ribosome is a ribonucleoprotein complex of ribosomal RNAs (rRNA) and proteins (r-protein). Conventionally, r-proteins are thought to be responsible for new protein synthesis, but emerging evidence has shown activity exists beyond this. Some extra-ribosomal functions of r-proteins have been observed in close relation to cancer pathology. MPS-1 is over-expressed in the serum and tissue of dozens of malignancies. However, it is unknown whether the enhanced expression of MPS-1 is the cause or result of tumor development and progression. Our preliminary observations show increased MPS-1 decreases paxillin. Recently, paxillin was found to have an important role in regulating both normal and tumor cell proliferation. 
     Elevation of MPS-1 in HNSCC samples and its structure/function as a ribosomal ZFP have led us to conclude that MPS-1 might be a subject of interest for malignant tumor therapy. Our data reveal that enhanced expression of MPS-1 protein can strongly suppress tumor cell proliferation. MPS-1 and significantly inhibits tumor growth both in vitro and in vivo in 3 distinct malignant cell lines. We have concluded that over-expression of MPS-1 might be used therapeutically in the treatment of some malignancies.
The invention discloses an LID-PEG-PLGA controlled-release nano microsphere and a preparation method thereof. The microsphere is the controlled-release microsphere which contains medicinal lidocaine and a degradable carrier. The degradable carrier contains polylactic-glycolic acid and PEG-2000. The mass percentage of the lidocaine in the controlled-release microsphere is 30 to 35 percent. The preparation method comprises the following steps of: preparing the carrier into matrix solution; dispersing the lidocaine into the matrix solution and preparing the lidocaine into an oil phase; mixing the oil phase and the aqueous solution of polyvinyl alcohol, and performing ultrasonic emulsification on the mixture under a water bath condition to obtain W/O-type protogala; mixing the W/O-type protogala and the aqueous solution of polyvinyl alcohol again, and further emulsifying the mixture into W/O/W-type complex emulsion; volatilizing the emulsion by reducing pressure at the normal temperature to obtain cured lidocaine-carried nano microsphere; and scattering, blending, packaging, freezing, sterilizing and the like. The medicament loading rate of the controlled-release nano microsphere can be up to 15 to 22 percent; the entrapment rate can be up to 68 to 78 percent; and the half-life period can be prolonged to 3 to 4 days. Therefore, the microsphere has relatively good effect of burst in the first day after the microsphere is taken and good effect of slow release in later days.
In the extra treatment (ET) group, standard endoscopic therapy will be performed to the bleeding peptic ulcer by local injection of diluted epinephrine 1:10 000 in combination with either heater probe coagulation, hemoclipping and/or rubber band ligation. Afterwards, we will apply 1.25g tranexamic acid powder via the endoscopy to the peptic ulcer before the end of endoscopic exam. After the first endoscopy, the patient will receive a 3-day continuous high-dose (8 mg/h) PPI infusion and Rockall score assessment as current guideline's recommendation. In patients with Rockall scores ≥6, after 3-day intravenous PPI infusion, we will apply oral twice-daily PPI for 11 days followed by once-daily PPI after then. In patients with Rockall scores \<6, we will apply once-daily PPI after 3-day intravenous PPI infusion. A second-look esophagogastroduodenoscopy (EGD) will be performed 2-3 days after the initial endoscopy, aiming to survey if major SRH of peptic ulcer persists.
An adherence device for tracking medication from a pill container is disclosed herein. In some instances, the adherence device comprises a band configured to be attached to the pill container, a housing attached to the band, and a button disposed about the housing. The button is configured to be depressed. The adherence device also includes a controller disposed within the housing. The controller is in communication with the button. The controller is configured to receive an indication that the button has been depressed and record that the button has been depressed.
Genomic instability contributes to cancer progression and is at least partly due to dysregulated homologous recombination (HR). Here, we show that an elevated level of ABL1 kinase overactivates the HR pathway and causes genomic instability in multiple myeloma (MM) cells. Inhibiting ABL1 with either short hairpin RNA or a pharmacological inhibitor (nilotinib) inhibits HR activity, reduces genomic instability, and slows MM cell growth. Moreover, inhibiting ABL1 reduces the HR activity and genomic instability caused by melphalan, a chemotherapeutic agent used in MM treatment, and increases melphalan's efficacy and cytotoxicity in vivo in a subcutaneous tumor model. In these tumors, nilotinib inhibits endogenous as well as melphalan-induced HR activity. These data demonstrate that inhibiting ABL1 using the clinically approved drug nilotinib reduces MM cell growth, reduces genomic instability in live cell fraction, increases the cytotoxicity of melphalan (and similar chemotherapeutic agents), and can potentially prevent or delay progression in patients with MM.